Leo says: "There is much greater value in the anti
Post# of 72440
Stressing that the LOWEST level helped the UP patients, and it was undetectable in the bloodstream -- minimal systemic exposure.
"We think that the latest data increases the value of Brilacidin many-fold."
Bril-OM, they're optimistic, more data in first half of 2017.
Kevetrin, phase 2A trial for ovarian cancer. Want to see exactly how K modulates p53 in the tumor. Oral formulation -- very exciting. Phase 1 was once a week by infusion. If they can take pill 2 or 3 times a day, 7 days a week -- they are excited.
Prurisol: was our dark horse. Following 2 successful clinical trials and a phase 2B PHARMAS ARE BEGINNING TO RECOGNIZE the value of Prurisol. HINT HINT !
psoriasis AND OTHER autoimmune disorders.
we're ahead of a rival drug
value of P could easily exceed current market cap
new possibilities cropping up from other things in intellectual property.